Connect with us

Hi, what are you looking for?

Sports

Ronaldo announces Al-Nassr chapter ‘over’

Ronaldo, 40, joined Al-Nassr in 2022 from Manchester United and his contract in Saudi Arabia ends this summer.

Ronaldo ended as the Saudi Pro League's top scorer this season on 24 goals
Ronaldo ended as the Saudi Pro League's top scorer this season on 24 goals - Copyright AFP Jim WATSON
Ronaldo ended as the Saudi Pro League's top scorer this season on 24 goals - Copyright AFP Jim WATSON

Portugal icon Cristiano Ronaldo indicated on Monday that he could leave Al-Nassr after declaring that a “chapter is over” hours after the Saudi Pro League finished.

Ronaldo, 40, joined Al-Nassr in 2022 from Manchester United and his contract in Saudi Arabia ends this summer.

A special transfer window runs from June 1-10 to allow the 32 clubs involved in the Club World Cup to sign players.

“This chapter is over,” Ronaldo cryptically said on social media with a photo of him in an Al-Nassr shirt.

“The story? Still being written.

“Grateful to all,” the former Real Madrid and Juventus attacker added.

Al-Nassr missed out on the Asian Champions League Elite, losing to Japan’s Kawasaki Frontale in April’s semi-finals and were third in the Saudi Pro League.

Ronaldo ended as the league’s top goal scorer on 24.

Last year, the five-time Ballon d’Or winner said he could end his career wit Al-Nassr.

AFP
Written By

With 2,400 staff representing 100 different nationalities, AFP covers the world as a leading global news agency. AFP provides fast, comprehensive and verified coverage of the issues affecting our daily lives.

You may also like:

Life

A dram of Ardbeg whisky. Image by Tim SandleEach May, to mark Ardbeg Day, the Ardbeg distillery releases a special expression of their range...

Social Media

Billie Piper's return may encourage a wider audience to tune in to determine the future direction of the show.

Tech & Science

Startup Genome’s 2025 report reveals a 31% global drop in startup value, while AI-native firms surge, now drawing 40% of all venture capital.

Tech & Science

A new tool could pave the way for new multi-target therapies, personalized medicine based on an analysis of genes.